Sarepta's Worst Week: Two Deaths, a Black Box, and 500 Pink Slips
Sarepta's Duchenne gene therapy Elevidys just got the FDA's most severe safety warning after fatal liver failures, while the company slashes 36% of its workforce and pivots away from gene therapy entirely. It's a brutal week that raises big questions about the future of the entire field.
Two boys died. That's how this story starts.
Both were non-ambulatory Duchenne muscular dystrophy patients, both pediatric, and both developed acute liver failure after receiving Sarepta's gene therapy Elevidys. Within weeks of infusion, their liver enzymes spiked. Hospitalization followed. Then the worst outcome imaginable.
Now the FDA has slapped Elevidys with a black box warning, its most severe safety label, for serious liver injury and acute liver failure, including fatal cases. And Sarepta? The company just announced it's cutting roughly 500 employees, about 36% of its workforce, in a restructuring that touches every corner of the organization.
This isn't a rough patch. This is a company in survival mode.
The Label That Changes Everything
A black box warning is the pharmaceutical equivalent of a neon "CAUTION" sign bolted to a drug's front door. Doctors see it first. Patients hear about it immediately. Payers use it as a reason to say no.
For Elevidys (delandistrogene moxeparvovec-rokl, if you enjoy tongue twisters), the warning specifically flags the risk of acute liver failure, including death. But the FDA didn't stop there. The agency also yanked the non-ambulatory indication entirely, meaning the drug is now restricted to patients who can still walk and are at least four years old.
That's a meaningful chunk of the addressable market, gone overnight.
The new label also comes with an intensive monitoring regimen: weekly liver function tests for at least three months after treatment. Patients need to stay near a specialized medical facility for at least two months post-infusion. And Sarepta must run a postmarketing study of about 200 patients followed for a year or more to better define the liver risk.
Think of it like buying a sports car that now comes with mandatory monthly inspections, a speed governor, and a clause that says the manufacturer has to watch you drive it for the next twelve months. Suddenly, fewer people want that car.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Three Deaths, One Platform, Zero Margin for Error
The two DMD fatalities weren't isolated. A third death occurred in a patient receiving one of Sarepta's related AAVrh74-based gene therapies for limb-girdle muscular dystrophy (LGMD). All three deaths involved acute liver failure. All three involved the same viral vector platform.
That pattern spooked the FDA enough to revoke Sarepta's AAVrh74 platform technology designation, a special status that had allowed the company to develop multiple therapies under a shared regulatory umbrella. Clinical holds were placed on Sarepta's LGMD trials. The FDA even requested that Sarepta halt Elevidys shipments entirely.
Sarepta initially pushed back, arguing there were no new safety signals in ambulatory patients. The company eventually paused all U.S. shipments voluntarily to negotiate the final label language. That tug-of-war with the FDA doesn't exactly inspire confidence in the relationship going forward.
500 People, $400 Million, and a Strategic U-Turn
The layoffs aren't just belt-tightening. They're a signal that Sarepta's entire business model is shifting.
The 500-person reduction spans R&D, clinical operations, regulatory, manufacturing, quality, and commercial teams. It's designed to generate roughly $400 million in annual cost savings starting in 2026, combining $120 million from personnel cuts with about $300 million from shelving programs.
Which programs? Most of the LGMD gene therapy pipeline is being paused or sent out for "strategic alternatives" (biotech-speak for "we'll license it to someone else if anyone's interested"). Sarepta's confirmatory study for Elevidys, the one meant to convert its accelerated approval into traditional (permanent) approval, has also been paused.
Instead, the company is pivoting toward siRNA-based therapies, a different technology platform targeting diseases like myotonic dystrophy, idiopathic pulmonary fibrosis, and Huntington's disease. It's a dramatic course correction: imagine a restaurant famous for its steak suddenly announcing it's going plant-based.
CEO Doug Ingram framed the move bluntly, saying that failure to adapt would "risk our long-term viability" and reduce the opportunity to help rare disease patients. The restructuring is partly about meeting 2027 financial obligations, including convertible notes coming due.
Wall Street's Emotional Rollercoaster
Investors had a complicated week.
When the black box warning and layoffs were first announced on July 16, Sarepta's stock surged roughly 33% in after-hours trading. The logic? At least the FDA wasn't pulling Elevidys off the market entirely for ambulatory patients. Evercore ISI told clients the warning actually "alleviates concerns about the possibility of the therapy being withdrawn from the market for ambulatory patients." In other words, it could have been worse.
But then news of the third death (the LGMD patient) hit, along with reports of the FDA shipment-halt dispute. The stock cratered dramatically. The relief rally evaporated faster than a biotech's post-IPO honeymoon.
Sarepta is now firmly in "show me" territory. Investors want to see stable safety data, a functional FDA relationship, and evidence that doctors are still willing to prescribe Elevidys for ambulatory patients. Management has already acknowledged that scheduled Elevidys appointments declined after the safety incidents.
What This Means for Gene Therapy's Reputation
Sarepta's crisis isn't just a Sarepta problem. It's a gene therapy problem.
In 2024, the FDA required class-wide black box warnings for CAR-T therapies (a different type of gene-modified treatment) due to T-cell malignancy risk. Now AAV gene therapies are getting their own scarlet letter. Pfizer recently discontinued its hemophilia gene therapy Beqvez amid weak uptake. The cumulative message to the market: these therapies carry real, sometimes fatal risks that don't always show up until after approval.
GlobalData analyst Momna Ali argued that Sarepta's situation puts the cell and gene therapy sector at a "critical juncture," emphasizing the need for greater transparency and sustainable innovation.
For the roughly 20 in every 100,000 boys born with Duchenne, the stakes couldn't be higher. The gene therapy market for DMD alone is projected to hit $640 million in the U.S. in 2026, with multiple competitors (Regenxbio, Solid Biosciences, Genethon, Pfizer) racing to bring next-generation alternatives. Those companies are now watching Sarepta's stumble very carefully, likely recalibrating their own safety monitoring plans and launch strategies.
The Bottom Line
Sarepta went from Duchenne gene therapy pioneer to cautionary tale in a matter of months. Two patient deaths triggered a black box warning, a narrowed label, and the loss of its platform technology designation. A third death deepened the crisis. The company responded with massive layoffs and a pivot away from the very technology that defined it.
The question now isn't whether Elevidys survives on the market. It probably does, in a diminished form. The real question is whether Sarepta can rebuild trust with doctors, families, regulators, and investors, all at the same time, with 36% fewer people to do it.
That's a tall order for any company. For one whose flagship product just got the FDA's strongest possible safety warning, it borders on Herculean.
4 min read
The FDA Just Created a Whole New Category of Cell Therapy
The FDA just approved the first-ever regulatory T-cell therapy, and it's not even close to a marginal improvement. Orca Bio's Tregzi doubled chronic GVHD-free survival in transplant patients, creating a whole new category of immunotherapy that has 29 other companies watching very carefully.
